Omthera Pharmaceuticals, Inc.

IN VITRO DIAGNOSTICS Alliances Abbott Laboratories Inc. Idera Pharmaceuticals Inc. Idera Pharmaceuticals Inc. (toll-like receptor (TLR) antagonists for autoimmune diseases and B-cell lymphomas) si

“The Pink Sheet” regularly presents commentary and perspective on key business deals. Here is a summary of the most noteworthy transactions that occurred between May 12 and May 16. Shire/Lumena Posit

As the door shuts on 2013 and we reflect on the year’s biopharma M&A activity, what’s most noteworthy is the activity of specialty pharmaceutical and big biotech companies, which supplanted big pharma

AstraZeneca PLC will buy out Bristol-Myers Squibb Co .’s interest in their diabetes alliance, including the drug assets, employees and infrastructure. In a structured deal, AZ is paying $2.7 billion